Peereboom, D., Lathia, J., Alban, T., Mohammadi, A., Ahluwalia, M., Brewer, C., & Vogelbaum, M. (2018). ACTR-09. TARGETING MYELOID DERIVED SUPPRESSOR CELLS: PHASE 0/1 TRIAL OF LOW DOSE CAPECITABINE + BEVACIZUMAB IN PATIENTS WITH RECURRENT GLIOBLASTOMA. Neuro Oncol.
Citação norma ChicagoPeereboom, David, Justin Lathia, Tyler Alban, Alireza Mohammadi, Manmeet Ahluwalia, Cathy Brewer, and Michael Vogelbaum. "ACTR-09. TARGETING MYELOID DERIVED SUPPRESSOR CELLS: PHASE 0/1 TRIAL OF LOW DOSE CAPECITABINE + BEVACIZUMAB IN PATIENTS WITH RECURRENT GLIOBLASTOMA." Neuro Oncol 2018.
Citação norma MLAPeereboom, David, et al. "ACTR-09. TARGETING MYELOID DERIVED SUPPRESSOR CELLS: PHASE 0/1 TRIAL OF LOW DOSE CAPECITABINE + BEVACIZUMAB IN PATIENTS WITH RECURRENT GLIOBLASTOMA." Neuro Oncol 2018.